Scientists at Stanford Medicine have identified a novel peptide, BRP, that mimics the appetite-suppressing effects of semaglutide (Ozempic) but with fewer side effects. Utilizing artificial intelligence, the research team discovered this peptide, which acts directly on the brain’s appetite-control center, leading to significant reductions in food intake and body weight in animal models without the nausea and muscle loss typically associated with current weight loss drugs.

The significance of BRP lies in its targeted mechanism of action. Unlike semaglutide, which affects multiple systems including the gut and pancreas, BRP specifically activates neurons in the hypothalamus, the brain region responsible for regulating appetite and metabolism. In trials with lean mice and minipigs, a single injection of BRP before feeding resulted in up to a 50% decrease in food consumption within an hour, and daily injections in obese mice led to an average weight loss of 3 grams over 14 days, primarily from fat. Importantly, these animals exhibited no adverse effects on movement, water intake, or anxiety levels, indicating a safer profile for potential human use.

The discovery of BRP could shift the landscape of obesity treatment by providing a more refined approach to appetite regulation. As researchers work to identify the specific receptors involved and extend the peptide’s effects for practical use, this advancement may accelerate the development of effective therapies for obesity, a condition that has long lacked adequate pharmacological options. With human clinical trials on the horizon, the implications for drug development timelines and therapeutic strategies in the field of metabolic disorders are substantial.

Source: sciencedaily.com